Antibody-drug conjugates: an evolving approach for melanoma treatment. Issue 1 (February 2021)

• Record Type: Journal Article
• Authors: Anderson, Trevor S.; Wooster, Amanda L.; La-Beck, Ninh M.; Saha, Dipongkor; Lowe, Devin B.
• Is Part Of: Melanoma research. Volume 31:Issue 1(2021)
• Publication Date: 2021-02
• Subjects: antibody-drug conjugate -- cancer -- immunotherapy -- melanoma; Melanoma -- Periodicals; Melanoma -- Periodicals; Melanomen; 616.99477
• DOI: 10.1097/CMR.0000000000000702
• Languages: English
• ISSNs: 0960-8931

Abstract

Abstract : Melanoma continues to be an aggressive and deadly form of skin cancer while therapeutic options are continuously developing in an effort to provide long-term solutions for patients. Immunotherapeutic strategies incorporating antibody-drug conjugates (ADCs) have seen varied levels of success across tumor types and represent a promising approach for melanoma. This review will explore the successes of FDA-approved ADCs to date compared to the ongoing efforts of melanoma-targeting ADCs. The challenges and opportunities for future therapeutic development are also examined to distinguish how ADCs may better impact individuals with malignancies such as melanoma.